NGL FINECHEM
Back to Balance Sheet
|
NGL FINECHEM Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹119 Cr | ₹87 Cr | ₹58 Cr | ₹66 Cr | ₹42 Cr |
What is the latest Total Current Liabilities ratio of NGL FINECHEM ?
| Year | Total Current Liabilities |
|---|---|
| Mar2025 | ₹119 Cr |
| Mar2024 | ₹87 Cr |
| Mar2023 | ₹58 Cr |
| Mar2022 | ₹66 Cr |
| Mar2021 | ₹42 Cr |
How is Total Current Liabilities of NGL FINECHEM Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹119 Cr | 37.40 | |
| Mar2024 | ₹87 Cr | 48.54 | |
| Mar2023 | ₹58 Cr | -11.21 | |
| Mar2022 | ₹66 Cr | 57.19 | |
| Mar2021 | ₹42 Cr | - | |
Compare Total Current Liabilities of peers of NGL FINECHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NGL FINECHEM | ₹868.0 Cr | 8.4% | 3.9% | -22.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹412,782.0 Cr | -1% | -4.9% | -7.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹168,376.0 Cr | -1.3% | -1.2% | 5.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹130,225.0 Cr | 0.2% | 2.8% | 12.2% | Stock Analytics | |
| CIPLA | ₹121,174.0 Cr | -0.3% | -1.1% | -0.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹104,629.0 Cr | -1.2% | -1.8% | -7.7% | Stock Analytics | |
NGL FINECHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NGL FINECHEM | 8.4% |
3.9% |
-22.4% |
| SENSEX | -0.3% |
-0.5% |
8.3% |
You may also like the below Video Courses